E-Book, Englisch, 368 Seiten, E-Book
Rothstein Pharmacogenomics
1. Auflage 2003
ISBN: 978-0-471-46120-3
Verlag: John Wiley & Sons
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
Social, Ethical, and Clinical Dimensions
E-Book, Englisch, 368 Seiten, E-Book
ISBN: 978-0-471-46120-3
Verlag: John Wiley & Sons
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
Through analyses of the complex underlying issues, thisinterdisciplinary volume frames the agenda for dealing with geneticvariation and incorporating pharmacogenomics into health care. Thethree sections of this book, Research Issues, Clinical Issues, andSocial Perspectives address key elements integral to acomprehensive discussion of this emerging field.
This groundbreaking text...
* Examines new research strategies, methodologies, and ethicaland social considerations of pharmacogenomics
* Addresses practical considerations of anticipated changes ineducation, training, oversight, guidelines and protocols, andcontinuing education requirements
* Provides analyses of the potential enormous impact ofpharmacogenomics, such as in the standard of care and treatment,including perspectives from the fields of anthropology, law,ethics, and economics
Autoren/Hrsg.
Weitere Infos & Material
Foreword (F. Collins).
Preface.
PART I: INTRODUCTION: SCIENCE AND SOCIETY.
Public Attitudes About Pharmacogenomics (M. Rothstein, etal.).
Pharmacogenomics: Pharmacology and Toxicology in theGenomics (H. Mohrenweiser).
The Implications of Population Genetics for Pharmacogenomics (C.Hanis).
PART II: RESEARCH AND DEVELOPMENT CHALLENGES ANDCONSIDERATIONS.
Genome Research and Minorities (H. Greely).
Drug Development Strategies (P. Manasco & T. Arledge).
Drug Development, Regulation, and Genetically GuidedTherapy Pharmacogenomics (D. Feigal & S. Gutman).
Intellectual Property and Commercial Aspects of Pharmacogenomics(A. Nunnally, et al.).
PART III: CLINICAL APPLICATIONS.
Integration of Pharmacogenomics into Medical Practice (G. Omenn& A. Motulsky).
Clinical Utility Pharmacogenetics and Pharmacogenomics (N.Holtzman).
Medical Liability for Pharmacogenomics (L. Palmer).
The Challenges of Pharmacogenomics for Pharmacy Education,Practice, and Regulation (D. Brushwood).
PART IV: THE SOCIAL DIMENSION.
Economic Implications of Pharmacogenomics (C. Reeder & W.Dickson).
Pharmacogenomics and the Social Construction of Identity(M. Foster).
Pharmacogenomics: Considerations for Communities of Color (L.Nsiah-Jefferson).
Constitutional Issues in the Use of Pharmacogenomic VariationsAssociated with Race (J. Robertson).
PART V: EPILOGUE: POLICY PRESCRIPTIONS (M. Rothstein).
Pharmacogenomics and Minority Populations: General PopulationSurvey Questionnaire (M. Rothstein).
Index.
